Abnormal fatty acid distribution of the serum phospholipids of patients with non-Hodgkin lymphoma

Cvetković, Zorica; Vučić, Vesna; Cvetković, B; Petrović, Milan; Ristić‐Medić, Danijela; Tepšić, Jasna; Glibetić, Maria

doi:10.1007/s00277-010-0904-6

Cited by 46 publications

(52 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Numerous studies have demonstrated that the significant decrease in linoleic acid (18:2, n-6) and increase in oleic acid (18:1n-9) were observed in plasma/serum/erythrocyte membrane phospholipids of patients with malignant diseases [30], such as bladder cancer [25,26], colorectal cancer [31], non-Hodgkin lymphoma [17] and prostatic carcinoma [6], which was consistent with our results. However, these changes were not in agreement with the results from breast cancer studies [32].…”

Section: Discussionsupporting

confidence: 94%

Abnormalities in Plasma Phospholipid Fatty Acid Profiles of Patients with Hepatocellular Carcinoma

Qiu

Zhang

et al. 2015

Lipids

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related death worldwide. In the present study, we aimed to profile the possible changes in plasma phospholipid fatty acid composition of HCC patients, and to identify the fatty acid biomarkers that could distinguish HCC patients from healthy controls. A total of 37 plasma samples from healthy controls and HCC patients were collected and their phospholipid fatty acid profiles were characterized by gas chromatography-mass spectrometry followed by multivariate statistical analysis. Twenty-five fatty acids were identified and quantified, their proportions varied greatly between two groups, suggesting each group has its own fatty acid pattern. Orthogonal partial least squares discriminant analysis in terms of fatty acid profiles showed that HCC patients could be clearly distinguished from healthy controls. More importantly, linoleic acid (18:2n-6), oleic acid (18:1n-9), arachidonic acid (20:4n-6) and palmitic acid (16:0) were identified as the potential fatty acid biomarkers of HCC patients. Additionally, to further identify the major cause of the abnormality of plasma fatty acid profile, fatty acid distributions of cancerous tissue and its surrounding tissue from 42 HCC patients were also examined. Due to have similar variation trend of major fatty acid biomarkers, linoleic acid (18:2n-6), oleic acid (18:1n-9), abnormalities in plasma phospholipid fatty acid profiles of HCC patients may be mainly attributed to the alternation of intrinsic fatty acid metabolism caused by cancer per se, but not to the differences in dietary factors.

show abstract

Section: Discussionsupporting

confidence: 94%

Abnormalities in Plasma Phospholipid Fatty Acid Profiles of Patients with Hepatocellular Carcinoma

Qiu

Zhang

et al. 2015

Lipids

View full text Add to dashboard Cite

show abstract

“…Indeed, DHA has been documented to have a range of anti-tumor effects, including inhibitory effects on tumor angiogenesis (5), apoptosis-inducing activity (6), inhibitory effects on tumor invasion and metastasis (7,8) and regulatory effects on signaling pathways (9). In addition, it has been documented that serum levels of omega-3 FAs in patients with pancreatic cancer, lung cancer or non-Hodgkin lymphoma were lower than those in healthy controls (25,26), with the lowest levels observed in patients with more advanced-stage cancer (26,27). It has also been demonstrated that DHA reduces metastasis in animal models using mice (7,8) and prevents the migration and invasion of human MDA-MB-231 mammary cancer cells in vitro (7).…”

Section: Discussionmentioning

confidence: 99%

Docosahexaenoic acid inhibits the phosphorylation of STAT3 and the growth and invasion of renal cancer cells

Tasaki

Horiguchi

Ito

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Docosahexaenoic acid (DHA) has a variety of anti-tumor activities. The present study examined the anti-tumor activity of DHA in renal cancer cells and its underlying mechanisms of action. The effects of DHA on the viability and proliferation of the human renal cancer cell lines Caki-1 and 786-O were examined by an MTS assay and cell counting. In addition, cell cycle distribution and cell apoptosis were analyzed by flow cytometry and Annexin V staining, and modulation of cell mobility and invasiveness was assessed by wound healing and Matrigel invasion assays. Effects of DHA on intracellular signaling pathways were also analyzed by western blotting. It was observed that DHA significantly reduced the viability and proliferation of Caki-1 and 786-O cells (P<0.01). Specifically, there were increases in the sub-G1 and G2/M cell populations, as well as the percentages of cells exhibiting Annexin-positive and propidium-iodide-negative staining. In addition, the covered area in a wound and the number of cells invading through a Matrigel chamber decreased when Caki-1 or 786-O cells were treated with DHA. Phosphorylation of epidermal growth factor receptor was also upregulated following DHA treatment, while phosphorylation of signal transducer and activator of transcription 3 and Akt was downregulated. Collectively, these data suggest that DHA may be useful in the treatment of renal cell carcinoma.

show abstract

“…27 The ratios of 20:4/20:3, 20:3/18:2 and 22:6/22:5 were used as a measure of estimated ∆5-desaturase, ∆6-desaturase and ∆4-desaturase activities respectively, while 18:1/18:0 and 18:0/16:0 ratios represented estimated ∆9-desaturase and elongase activities.…”

Section: Estimated Activities Of Desaturase Systemmentioning

confidence: 99%

Effects of n–3 Supplementation on Plasma and Liver Phospholipid Fatty Acids Profile in Aged Wistar Rats

Popović¹,

Borozan²,

Arsić³

et al. 2011

Croat. Chem. Acta

Self Cite

View full text Add to dashboard Cite

Abstract. The effects of fish oil supplementation in Wistar rats are focused on cardiovascular, endocrine, metabolic and antioxidant status changes. We determined plasma and liver phospholipid fatty acids (FAs) status and plasma lipid concentrations in aged Wistar rats. Our results showed differences in plasma and liver FAs profiles as well as plasma chlolesterol (CHOL), triglicerides (TG), high density lipoproteins (HDL), low density lipoproteins (LDL), CHOL/HDL ratio (risk factor for atherosclerosis) and LDL/HDL ratio (risk for cardiovascular diseases) between treated and control group of animals. In fish oil treated group there were statistically significant changes in FAs profile in increasing linoleic acid (LA), dihomo-γ linoleic acid, eicopentanoic acid (EPA) and docosapentaenoic acid (DPA) and decreasing in arachidonic acid (AA) concentration. Also, liver phospholipids FAs results showed increasing concentrations of vascenic acid, LA, EPA, and DPA and decreasing concentration of AA after supplementation of fish oil compared to control group. However, concentrations of CHOL, LDL and non HDL concentrations decreased while HDL increased in fish oil group. CHOL/HDL, LDL/HDL ratios decreased. These findings suggest that long term treatment of fish oil in aged Wistar rats can be beneficial in decreasing LDL, and decreasing risk factors for developing atherosclerosis and cardiovascular diseases. (doi: 10.5562/cca1751)

show abstract

Abnormal fatty acid distribution of the serum phospholipids of patients with non-Hodgkin lymphoma

Cited by 46 publications

References 35 publications

Abnormalities in Plasma Phospholipid Fatty Acid Profiles of Patients with Hepatocellular Carcinoma

Abnormalities in Plasma Phospholipid Fatty Acid Profiles of Patients with Hepatocellular Carcinoma

Docosahexaenoic acid inhibits the phosphorylation of STAT3 and the growth and invasion of renal cancer cells

Effects of n–3 Supplementation on Plasma and Liver Phospholipid Fatty Acids Profile in Aged Wistar Rats

Contact Info

Product

Resources

About